Patents by Inventor George L. Spitalny

George L. Spitalny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of reducing basophil levels
    Patent number: 9815895
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 14, 2017
    Assignees: BIOWA, INC., ASTRAZENECA AB
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Methods Of Reducing Eosinophil Levels
    Publication number: 20140004109
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 2, 2014
    Applicants: Medlmmune, LLC, Biowa, Inc.
    Inventors: Masamichi Koike, George L. SPITALNY, Alistair WHEELER, Barbara WHITE
  • Methods of reducing eosinophil levels
    Patent number: 8501176
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: August 6, 2013
    Assignees: MedImmune, LLC, BIOWA, Inc.
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Methods Of Reducing Eosinophil Levels
    Publication number: 20120148575
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Application
    Filed: July 6, 2011
    Publication date: June 14, 2012
    Applicants: BIOWA, INC., Medlmmune, LLC
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • METHODS OF REDUCING EOSINOPHIL LEVELS
    Publication number: 20100291073
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e g, esophagus, stomach, small intestine and colon), or lung.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 18, 2010
    Applicants: MEDIMMUNE, LLC, BIOWA, INC.
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
    Patent number: 5728399
    Abstract: An improved soluble molecular complex for targeting a polynucleotide to a specific cell is disclosed. The molecular complex comprises (a) a polynucleotide (b) a carrier made up of a polynucleotide binding agent and a cell-specific binding agent which binds to a surface molecule of the cell and is internalized into an endosome, and (c) a bacterial component or fragment thereof which lyses the endosome and causes the polynucleotide to be released into the cytoplasm of the cell. In a preferred embodiment of the invention the polynucleotide binding agent is polylysine, the cell-specific binding agent is an asialoglycoprotein, and the bacterial component is listeriolysin O. The disclosed soluble molecular complex and methods of use can be used therapeutically to deliver genes and antisense polynucleotides to specific cells in vivo.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 17, 1998
    Assignees: University of Conn., TargeTech, Inc. a wholly owned subsidiary of The Immune Response Corporation
    Inventors: George Y. Wu, Catherine H. Wu, Ying Zhang, George L. Spitalny, Ellen Carmichael